

Multicenter, open-label, phase-II-trial to evaluate the efficacy and safety of low-radiofrequency deep hyperthermia with capacitive coupled electrodes (LRF-DHT) in treating patients with recurrent high-grade malignant gliomas

**Dr. Dr. E. Dieter Hager¹, Dr. Fiedrich Migeod¹, Dr. Hüseyin Sahinbas²,
Prof. Dr. Dietrich Grönemeyer², Dr. E. Böcher³**

(1) BioMed-Klinik, Bad Bergzabern, Germany

(2) Witten/Herdecke University, Germany

(3) Klinik Kloster Paradiese, Soest, Germany

Multicenter, open-label, phase-II-trial to evaluate the efficacy and safety of low-radiofrequency deep hyperthermia with capacitive coupled electrodes (LRF-DHT) in treating patients with recurrent high-grade malignant gliomas

Dr. Dr. E. Dieter Hager¹, Dr. Friedrich Migeod¹, Dr. Hüseyin Sahinbas², Prof. Dr. Dietrich Grönemeyer², Dr. E. Böcher³

(1) BioMed-Klinik, Bad Bergzabern, Germany

(2) Witten/Herdecke University, Germany

(3) Klinik Kloster Paradiese, Soest, Germany

LRF-DHT is feasible in treating patients with brain tumours without any severe side effects. LRF-DHT may induce complete impartial remissions. Overall median survival time (MST) could be increased by 13 and 7 months from onset of LRF-DHT after progression or recurrence in grade III and grade IV gliomas (astrocytoma WHO III, Glioblastoma muliforme WHO IV). Quality of life and overall survival could be improved by this method compared to historical control groups. Further trials are urgently warranted.